proof
principl
antibodi
could
effici
express
target
differ
intracellular
compart
mammalian
cell
date
biocca
et
al
led
concept
exploit
recombin
antibodi
block
modul
function
target
antigen
intercellular
intracellular
immun
biocca
cattaneo
cattaneo
biocca
intrabodi
uniqu
advantag
compar
knockout
gene
techniqu
rna
interfer
first
target
antigen
differ
intracellular
compart
includ
extracellular
milieu
secondli
highli
specif
reagent
stabl
mammalian
cell
especi
express
secretori
compart
addit
intrabodi
hit
varieti
possibl
target
specif
protein
domain
ii
specif
proteinprotein
interact
site
iii
posttransl
modif
iv
multipl
conform
isoform
oligom
fibril
etc
v
even
non
protein
antigen
order
specif
target
intrabodi
physiolog
site
antigen
new
intracellular
localis
domin
autonom
target
sequenc
graft
onto
antibodi
chain
recombin
antibodi
domain
particular
singlechain
fv
scfv
fragment
express
cytoplasm
biocca
et
al
nucleu
duan
et
al
mhashilkar
et
al
secretori
pathway
mammalian
cell
marasco
et
al
success
use
inhibit
function
sever
intracellular
antigen
new
suitabl
antibodi
format
intracellular
use
avail
function
intrabodi
employ
research
tool
defin
mechan
human
patholog
molecular
level
varieti
therapeut
applic
instanc
intrabodi
design
inhibit
singl
simultan
multipl
signal
transduct
pathway
lener
et
al
tanaka
et
al
jendreyko
et
al
inhibit
hiv
viral
protein
lo
et
al
inhibit
oncogen
product
william
zhu
griffin
et
al
misfoldingpron
protein
cardinal
biocca
receptor
immun
system
kirschn
et
al
also
appli
posttransplant
surgeri
zdoroveac
et
al
antibodi
fragment
direct
specif
target
antigen
present
cytosol
nucleu
endoplasm
reticulum
er
plasma
membran
pm
mitochondria
peroxisom
transgolgi
network
tgn
frame
fusion
intracellular
traffick
sequenc
cardinal
et
al
follow
list
target
signal
success
use
intracellular
express
antibodi
way
target
intrabodi
throughout
secretori
pathway
secret
protein
exploit
leader
sequenc
secret
immunoglobulin
ig
n
terminu
erretain
intrabodi
design
leader
sequenc
n
terminu
retent
peptid
kdel
c
terminu
biocca
et
al
intrabodi
er
behav
intracellular
anchor
use
either
prevent
appear
receptor
protein
plasma
membran
inhibit
secret
protein
similar
protein
retent
transgolgi
achiev
transgolgi
retent
signal
zhou
et
al
target
plasma
membran
obtain
fuse
scfv
receptor
transmembran
domain
chesnut
et
al
remov
leader
sequenc
variabl
heavi
vh
variabl
light
vl
domain
target
antibodi
fragment
lumen
endoplasm
reticulum
allow
cytoplasm
express
intrabodi
leaderless
nuclear
target
achiev
ad
one
nuclear
localis
sequenc
nl
leaderless
antibodi
fragment
pkkkrkv
sequenc
larg
antigen
either
n
cterminu
biocca
et
al
intrabodi
also
target
mitochondria
ntermin
presequ
present
nuclearencod
mitochondri
protein
sequenc
remov
protein
transloc
mitochondri
membran
ntermin
presequ
subunit
viii
human
cytochrom
oxidas
cover
cleavag
junction
fuse
scfv
fragment
result
molecul
correctli
local
mitochondria
biocca
et
al
facilit
express
scfv
fragment
secret
intracellular
protein
set
gener
vector
design
integr
system
scfvexpress
vector
persic
et
al
deriv
vhexpress
vector
vector
use
produc
secretori
immunoglobulin
heavi
chain
clone
igh
region
persic
et
al
scfvexpress
plasmid
contain
n
ctermin
localis
signal
allow
target
antibodi
fragment
differ
compart
includ
endoplasm
reticulum
scfvexer
cytoplasm
scfvexcyt
nucleu
scfvexnuc
mitochondria
scfvexmit
scfvexpresscyt
target
signal
leaderless
direct
express
scfv
cytoplasm
ntermin
methionin
instead
leader
sequenc
secret
target
vector
deriv
scfvexpresscyt
obtain
insert
well
character
target
signal
biocca
et
al
either
n
ctermin
scfv
appropri
besid
specif
target
signal
vector
contain
cassett
encod
strong
promot
sequenc
resist
select
antibiot
ctermin
myctag
frame
scfv
allow
detect
monoclon
antibodi
persic
et
al
vector
use
transient
stabl
transfect
mammalian
cell
innov
dna
recombin
technolog
allow
reformat
antibodi
molecul
new
smaller
fragment
improv
properti
intracellular
express
far
singl
chain
variabl
fragment
scfv
recombin
antibodi
format
wide
use
intrabodi
contain
complet
antigen
bind
site
consist
variabl
domain
immunoglobulin
heavi
vh
light
vl
chain
link
flexibl
polypeptid
prevent
dissoci
result
molecul
monoval
antibodi
fragment
molecular
weight
kda
compar
kda
fulllength
antibodi
format
success
express
insid
cell
recombin
bispecif
tetraval
antibodi
fragment
made
two
scfv
link
second
third
heavi
chain
constant
domain
name
intradiabodi
bispecif
intrabodi
design
simultan
trap
two
endotheli
transmembran
receptor
compart
jendreyko
et
al
scfv
minim
size
function
antibodi
fragment
fragment
made
one
variabl
domain
singl
vl
vh
domain
smallest
function
fragment
deriv
immunoglobulin
light
heavi
chain
socal
vhh
singl
domain
antibodi
fragment
deriv
natur
occur
heavychain
antibodi
devoid
light
chain
present
immun
system
camelid
retain
antigen
specif
whole
antibodi
excel
properti
solubl
stabil
express
mammalian
cell
asid
absenc
intradomain
disulfid
bond
hamerscasterman
et
al
wesolowski
et
al
easili
produc
recombin
antibodi
much
smaller
size
forg
new
multispecif
multival
reagent
enhanc
therapeut
efficaci
due
smaller
size
possess
great
capac
form
long
fingerlik
extens
potenti
target
cryptic
epitop
difficult
intact
antibodi
scfv
fragment
reach
antibodi
fragment
potenti
target
subcellular
compart
fold
perform
stabil
limit
microenvironment
intracellular
condit
compart
direct
thu
major
issu
rais
initi
phase
work
intrabodi
limit
half
life
antibodi
antibodi
domain
tendenc
aggreg
express
cytoplasm
mammalian
cell
studi
target
scfv
fragment
show
fact
express
level
retarget
antibodi
domain
may
vari
cytoplasm
may
consid
worst
case
cattaneo
biocca
gener
intrabodi
express
secretori
compart
stabl
express
cytoplasm
due
fact
intradomain
disulfid
bond
contribut
kcal
stabil
antibodi
domain
form
reduc
environ
cytoplasm
biocca
et
al
consequ
lower
stabil
scfv
tend
misfold
aggreg
insolubl
protein
notwithstand
fact
worth
note
mani
case
cytoplasmictarget
intrabodi
bind
antigen
maintain
vivo
function
activ
cardinal
et
al
recent
compar
studi
cytoplasm
express
mammalian
cell
well
character
singlechain
variabl
fragment
camelid
vhh
select
antibodi
librari
base
similar
scaffold
outlin
physicochem
determin
correl
enhanc
intracellular
solubl
solubl
express
cytoplasm
appear
influenc
complementari
determin
region
cdr
content
overal
charg
hydropath
intrabodi
sequenc
kvam
et
al
issu
import
last
year
mani
select
strategi
develop
improv
stabil
solubl
function
properti
antibodi
fragment
condit
intracellular
express
two
differ
strategi
follow
knowledgebas
selectionbas
approach
former
reli
introduct
educ
mutat
stabil
preexist
antibodi
fragment
order
obtain
superframework
jung
et
al
monselli
bedouel
second
approach
exploit
avail
differ
antibodi
librari
select
best
function
molecul
intracellular
express
hudson
souriau
express
cytoplasm
new
human
phage
antibodi
librari
gener
base
singl
framework
optim
intracellular
express
philibert
et
al
hand
highli
stabl
ribosomedisplay
librari
base
escherichia
coli
secm
translat
arrest
mechan
use
isol
scfv
stabl
reduc
condit
delisa
moreov
antibodyantigen
intracellular
select
method
also
develop
isol
intrabodi
abl
effici
interact
antigen
vivo
aim
vivo
yeast
twohybrid
system
realiz
describ
intracellular
antibodi
captur
iac
technolog
visintin
et
al
approach
combin
first
round
vitro
select
scfv
second
round
vivo
screen
select
intrabodi
allow
isol
antibodi
domain
need
use
purifi
antigen
iac
technolog
recent
allow
direct
vivo
intracellular
select
conformationsensit
antioligomer
scfv
alzheim
amyloid
peptid
meli
et
al
anoth
procedur
direct
vivo
select
antigenspecif
intrabodi
utilis
singl
domain
antibodi
format
base
predefin
intrabodi
consensu
framework
describ
tanaka
rabbitt
develop
tanaka
rabbitt
new
protocol
allow
isol
function
vh
vl
domain
differ
librari
four
step
includ
confirm
function
intrabodi
mammalian
cell
clinic
applic
intrabodi
gener
human
andor
humanderiv
antibodi
domain
offer
obviou
potenti
advantag
modern
emerg
strategi
improv
vitro
select
fulli
human
recombin
antibodi
directli
human
antibodydisplay
librari
creation
larg
natur
synthet
repertoir
antibodi
fragment
hudson
souriau
hoogenboom
direct
select
human
phage
antibodi
librari
tumor
cell
describ
goenaga
et
al
intrabodi
mediat
effect
insid
cell
neutral
target
protein
direct
bind
function
domain
biocca
et
al
cohen
et
al
block
proteinprotein
interact
griffin
et
al
tanaka
et
al
van
den
abbeel
et
al
reloc
antigen
differ
intracellular
locat
lener
et
al
cardinal
et
al
last
case
also
nonneutr
antibodi
accord
vitro
biochem
criteria
effect
express
vivo
obtain
ad
intrabodi
specif
target
signal
er
retent
signal
kdel
confer
antigenantibodi
complex
retent
endoplasm
reticulum
describ
case
intrabodi
divert
antigen
proteasom
degrad
pathway
cardinal
et
al
filesi
et
al
mention
intrabodi
differ
fold
perform
stabil
particularli
express
cytoplasm
compart
intradomain
disulfid
bond
form
intrabodi
complex
correspond
antigen
tend
misfold
aggreg
demonstr
cytoplasm
nuclear
secretori
intrabodi
first
case
aggreg
form
aggresom
perinuclear
locat
wherea
secretori
compart
antigenantibodi
complex
retrotransloc
er
ubiquitin
final
proteasom
degrad
filesi
et
al
order
defin
mode
action
new
intrabodi
solubl
properti
intracellular
distribut
result
phenotyp
routin
analys
ad
hoc
assay
protocol
studi
express
solubl
stabil
properti
intracellular
localis
analysi
antigenintrabodi
complex
vivo
describ
cardinal
et
al
cardinal
biocca
summari
intrabodi
use
prevent
treat
human
diseas
exploit
abil
divert
antigen
function
locat
b
inhibit
function
proteinprotein
interact
c
inhibit
function
site
target
antigen
rerout
antigen
degrad
pathway
e
inhibit
differ
stage
aggreg
process
latter
mode
action
achiev
stabil
nativ
state
isoform
inhibit
oligomer
inhibit
fibril
format
disrupt
clearanc
preform
aggreg
demonstr
scfv
direct
misfold
prone
protein
cardinal
biocca
figur
summaris
differ
mode
action
intrabodi
observ
vivo
activ
great
potenti
medicin
repres
viabl
option
differ
patholog
includ
neurodegen
diseas
infecti
diseas
cancer
hallmark
misfold
diseas
accumul
amyloid
amyloidlik
aggreg
deriv
fibril
process
nativ
protein
aggreg
process
amyloidogen
protein
mani
differ
conform
includ
misfold
monom
oligom
fibril
gener
chiti
dobson
neurodegen
diseas
aggreg
occur
brain
accompani
cognit
declin
avail
therapeut
treatment
slow
prevent
devast
disord
still
effect
develop
new
molecular
therapi
target
pathogen
protein
urgent
need
particular
great
interest
search
new
molecul
abl
prevent
unfold
aggreg
either
stabil
nativ
state
amyloidogen
precursor
disassembl
amyloid
fibril
conform
specif
antibodi
promis
agent
neurodegen
disord
rais
differ
structur
isoform
amyloidogen
antigen
act
protein
level
use
intrabodi
approach
fig
interestingli
although
obviou
structur
sequenc
ident
among
protein
caus
neurodegen
diseas
shown
conformationdepend
antibodi
rais
molecular
mimic
oligom
react
oligom
deriv
differ
kind
amyloidogen
protein
polyglutamin
prion
etc
inhibit
toxic
associ
aggreg
kay
et
al
find
indic
conform
structur
rather
amino
acid
sequenc
misfold
isoform
probabl
key
factor
neurotox
gener
conformationspecif
intrabodi
therapeut
purpos
use
either
iac
technolog
need
purifi
antigen
meli
et
al
crucial
isol
specif
misfold
isoform
case
atom
forc
microscopi
afm
electron
microscopi
method
allow
visualis
differ
isoform
even
small
oligom
combin
phage
display
technolog
screen
afm
use
new
approach
select
morphologyspecif
intrabodi
differ
conform
report
fibril
oligom
emadi
et
al
marcu
et
al
zameer
et
al
mani
recombin
intrabodi
protein
involv
pathogenesi
alzheim
prion
huntington
parkinson
diseas
gener
success
express
cellular
anim
model
cardinal
biocca
alzheim
diseas
ad
common
form
dementia
character
extracellular
deposit
intracellular
accumul
amyloid
beta
peptid
hyperphosphoryl
tau
protein
blennow
et
al
either
peripher
central
nervou
system
cn
target
antibodi
larg
use
prove
effect
reduc
placqu
burden
memori
impair
steinitz
paganetti
et
al
gener
intrabodi
direct
efrh
peptid
adjac
cleavag
site
human
amyloid
precursor
protein
app
express
along
secretori
pathway
shield
cleavag
site
inhibit
format
toxic
kdel
version
intrabodi
effect
sinc
anchor
app
er
prevent
appear
plasma
membran
paganetti
et
al
anoth
studi
express
antinicastrin
intrabodi
disrupt
proper
fold
glycosyl
endogen
nicastrin
protein
requir
stabil
complex
result
antinicastrin
intrabodi
suppress
enzymat
activ
vivo
hayashi
et
al
prion
diseas
fatal
transmiss
spongiform
encephalopathi
affect
human
anim
prusin
aguzzi
et
al
far
intrabodi
applic
prion
disord
target
endogen
prion
protein
prpc
antiprion
scfv
fragment
gener
stabli
express
neuron
cell
line
suscept
scrapi
infect
intracellular
express
caus
mark
impair
prion
matur
transloc
toward
membran
compart
strong
reduct
prpc
membran
fraction
consequ
pathogen
scrapi
isoform
prpsc
form
accumul
infect
cell
cardinal
et
al
moreov
mice
intracerebr
inject
lysat
deriv
express
cell
infect
scrapi
neither
develop
scrapi
clinic
sign
brain
damag
demonstr
effect
treatment
vetrugno
et
al
secretori
version
intrabodi
abl
recogn
prpc
secretori
pathway
strongli
inhibit
prpsc
accumul
scrapi
strain
infect
cell
analys
mode
action
found
prpc
total
level
markedli
reduc
due
select
rerout
prpc
proteasom
pathway
moreov
intrabodi
impair
secret
endogen
prion
molecul
associ
exosomeslik
vesicl
potenti
spread
rout
prion
infect
filesi
et
al
drastic
reduct
prpsc
accumul
also
obtain
cocultur
cell
secret
antiprion
scfv
fragment
chronic
scrapi
infect
neuroblastoma
cell
donofrio
et
al
huntington
diseas
hd
genet
disord
associ
progress
neurodegener
brain
area
cortex
striatum
walker
caus
aggreg
mutat
form
huntingtin
htt
protein
present
abnorm
long
polyglutamin
poliq
sequenc
ntermin
cytoplasm
intrabodi
direct
polyprolin
region
flank
polyglutamin
region
ctermin
side
htt
inhibit
cell
death
aggreg
transient
transfect
cell
intrabodi
polyq
region
cytotox
ineffect
acceler
aggreg
format
apoptot
cell
death
khoshnan
et
al
phagederiv
scfv
ntermin
portion
htt
reduc
aggreg
toxic
cell
cultur
neuron
organotyp
slice
cultur
drosophila
model
hd
murphi
messer
wolfgang
et
al
mclear
et
al
anoth
potent
intrabodi
mutant
htt
express
striatum
hd
mice
via
adenovir
infect
reduc
neuropil
aggreg
format
amelior
neurolog
symptom
wang
et
al
interact
intrabodi
mutant
huntingtin
increas
ubiquitin
cytoplasm
htt
degrad
indic
intrabodymedi
rerout
htt
proteasom
pathway
mechan
underli
protect
activ
fig
furthermor
intrabodi
ntermin
htt
anoth
recogn
prolin
rich
domain
htt
prevent
htt
aggreg
inhibit
toxic
immort
striatal
cell
model
hd
differ
mechan
southwel
et
al
test
brain
five
mous
model
hd
increas
sever
phenotyp
mortal
two
model
treatment
amelior
motor
cognit
neuropatholog
symptom
southwel
et
al
parkinson
diseas
pd
second
preval
neurodegen
ill
clinic
character
motor
cognit
dysfunct
main
neuropatholog
featur
presenc
intracytoplasm
proteinac
inclus
term
lewi
bodi
lb
woodkaczmar
et
al
protein
major
structur
compon
lb
cytoplasm
express
antimonomer
singlechain
intrabodi
rescu
cell
adhes
stabil
monomer
isoform
inhibit
format
high
molecular
weight
insolubl
speci
cell
model
zhou
et
al
recent
novel
intrabodi
nonamyloid
compon
select
yeast
surfac
display
librari
show
highli
signific
reduct
aggreg
stabli
trasfect
cellular
model
lynch
et
al
antioligomer
scfv
fragment
block
fibril
format
vitro
emadi
et
al
allevi
toxic
intracellularli
express
mammalian
cell
yuan
sierk
oculopharyng
muscular
dystrophi
opmd
autosom
domin
dystrophi
clinic
character
progress
weaken
specif
muscl
protein
aggreg
disord
caus
short
expans
ntermin
polyalanin
tract
nuclear
poli
bind
protein
mutant
aggreg
intranuclear
inclus
opmd
patient
muscl
order
inhibit
aggreg
mutant
panel
specif
singl
domain
antibodi
fragment
vh
express
cellular
anim
opmd
model
one
effect
reduc
aggreg
format
clear
preexist
aggreg
cell
strong
suppressor
muscl
degener
character
drosophila
opmd
model
restor
muscl
gene
express
verheesen
et
al
chartier
et
al
develop
intrabodi
inhibit
viru
structur
regulatori
enzymat
envelop
protein
receptor
surfac
host
cell
also
larg
explor
demonstr
efficaci
either
earli
late
event
viral
life
cycl
begin
use
target
protein
human
immunodefici
viru
lo
et
al
intrabodi
equip
er
retent
signal
employ
viral
coat
protein
caus
inhibit
viru
replic
syncyti
format
marasco
et
al
zhou
et
al
inhibit
earli
late
event
life
cycl
also
obtain
express
cytoplasm
intrabodi
direct
matrix
protein
levin
et
al
protein
involv
replic
revers
transcriptas
vif
camel
singledomain
intrabodi
effici
interact
vif
protein
neutral
vifmedi
provir
integr
non
permiss
cell
air
da
silva
et
al
moreov
intrabodi
block
regulatori
protein
tat
rev
use
inhibit
replic
cytosol
antitat
scfv
fragment
modifi
ctermin
human
c
kappa
domain
increas
cytoplam
stabil
inhibit
tatmedi
long
termin
repeat
ltr
transactiv
infect
transform
lymphocyt
mhashilkar
et
al
bai
et
al
cytosol
antirev
scfv
fragment
inhibit
replic
cell
duan
et
al
recent
llama
deriv
vh
domain
select
ntermin
multimer
domain
rev
use
block
rev
multimer
prevent
hiv
replic
vercruyss
et
al
intrabodi
describ
treatment
variou
viral
infect
hepat
b
hbv
hepat
c
viru
hcv
infect
repres
global
health
problem
erretain
singledomain
intrabodi
vhh
target
envelop
protein
hbv
induc
two
log
reduct
virion
secret
hbv
mous
model
serruy
et
al
still
preliminari
studi
cytosol
nuclear
vhh
intrabodi
target
core
antigen
hbcag
produc
test
infect
cell
serruy
et
al
intrabodi
serin
proteas
necessari
viral
replic
innat
immun
evas
inhibit
hcv
replic
express
hepatoma
cell
galtanami
et
al
intrabodi
inhibit
papilloma
viru
protein
function
cervic
cancer
cell
griffin
et
al
decreas
kaposi
sarcomaassoci
herp
viral
persist
lymphoma
cell
corter
et
al
reduc
transcript
replic
influenza
viru
mukhtar
et
al
interestingli
novel
disulfidefre
protein
target
sever
acut
respiratori
syndrom
sar
n
protein
high
affin
select
gener
use
mrna
display
select
direct
evolut
although
molecul
structur
differ
antibodi
utilis
discontinu
bind
surfac
may
repres
interest
altern
intrabodi
least
molecul
test
studi
seven
block
sar
replic
differ
effici
disrupt
mammalian
cell
function
liao
et
al
mani
tumor
character
presenc
mutat
aberrantli
express
protein
involv
control
vital
process
oncogen
protein
locat
insid
cell
avail
target
standard
antibodymedi
antitumor
therapi
intrabodi
clear
clinic
potenti
cancer
therapi
success
use
effector
intracellular
cancer
target
pathway
associ
tumor
cell
prolifer
differenti
invas
particular
intrabodi
extens
studi
inhibitor
growth
factor
receptor
oncogen
antigen
secretori
compart
cytoplasm
nuclei
aberr
express
member
epiderm
growth
factor
receptor
egfr
famili
egfr
observ
varieti
human
tumor
includ
breast
ovari
carcinoma
mani
report
describ
success
phenotyp
knockout
epiderm
growth
factor
receptor
egfr
achiev
retent
erretain
scfv
intrabodi
grausporta
et
al
jannot
et
al
deshan
et
al
regul
surfaceexpos
receptor
result
induct
apoptosi
cytotox
inhibit
tumor
cell
prolifer
vitro
vivo
howev
phase
clinic
trial
use
scfvencod
adenoviru
carri
treat
ovarian
cancer
highlight
need
effici
gene
deliveri
system
alvarez
et
al
revers
transform
phenotyp
ovarian
cancer
cell
also
obtain
intracellular
express
erretain
folat
receptor
intrabodi
figini
et
al
identifi
function
character
tumor
specif
marker
human
scfv
phage
display
librari
use
select
intrabodi
abl
bind
rapidli
intern
human
breast
cancer
one
prove
knock
surfac
display
partner
tumor
specif
receptor
antigen
express
erretain
intrabodi
insid
cell
goenaga
et
al
ra
guanin
nucleotid
bind
protein
play
crucial
role
regul
cell
prolifer
oncogen
transform
differenti
locat
inner
surfac
plasma
membran
panel
non
neutral
antira
scfv
prove
inhibit
cell
prolifer
sequest
antigen
divert
cytoplasm
aggresom
lener
et
al
intrabodymedi
ra
aggreg
led
proteasom
dysfunct
apoptosi
cardinal
et
al
anoth
studi
neutral
ra
promot
apoptosi
human
cancer
cell
led
tumor
regress
colon
carcinoma
tumour
model
nude
mice
cochet
et
al
recent
solubl
singl
vh
domain
specif
bind
activ
gtpbound
ra
inhibit
raseffector
protein
interact
ra
prevent
tumorigenesi
mous
model
tanaka
et
al
tumor
suppressor
gene
mutat
almost
half
human
tumor
restor
transcript
activ
may
trigger
massiv
apoptosi
cancer
cell
intracellular
express
nuclear
target
scfv
fragment
human
tumor
cell
lead
restor
mutant
defici
transcript
activ
caron
de
fromentel
et
al
induc
tumor
regress
anim
model
mice
carri
human
xenograft
appar
deleteri
side
effect
orgad
et
al
function
apoptot
pathway
crucial
cell
homeostasi
elimin
damag
transform
cell
dysregul
apoptosi
implic
mani
patholog
includ
neurodegen
diseas
cancer
two
camelidderiv
singl
vh
domain
select
recombin
express
intrabodi
neuroblastoma
cell
line
show
differ
vivo
apoptoticmodul
effect
notabl
one
antagonist
toward
caspas
protect
cell
oxidativestressinduc
apoptosi
abl
induc
cell
death
mcgonig
et
al
recent
applic
use
intrabodi
antitoxin
agent
toxin
microbi
sourc
continu
caus
substanti
human
veterinari
patholog
repres
seriou
biosecur
threat
current
antidot
revers
symptom
botulinum
neurotoxin
camelid
singl
domain
intrabodi
vhh
specif
select
clostridium
botulinum
neurotoxin
bont
protect
neuron
cell
synaptosomalassoci
protein
protein
cleavag
demonstr
potenti
compon
therapeut
agent
botul
intox
tremblay
et
al
adpribosyl
toxin
salmonella
spvb
toxin
secret
directli
salmonellacontain
vacuol
cytosol
target
cell
thu
inaccess
convent
antibodi
singledomain
antibodi
express
cytosol
intrabodi
block
actin
adpribosyl
toxin
salmonella
typhimurium
alzogaray
et
al
target
antigen
access
circul
antibodi
molecul
power
intrabodi
technolog
approach
greatli
improv
recent
advanc
scaffold
design
repertoir
construct
ad
hoc
select
method
improv
stabil
solubl
intrabodi
insid
cell
camelid
deriv
singl
domain
antibodi
smallest
fragment
intracellularli
express
repres
new
gener
intrabodi
capac
enter
small
caviti
antigen
high
solubl
good
tissu
penetr
still
major
problem
solv
intrabodi
clinic
approv
therapeut
agent
includ
particular
develop
appropri
effici
safe
deliveri
strategi
term
transduct
system
rout
deliveri
adenoassoci
aav
viral
vector
still
repres
best
choic
deliveri
mammalian
tissu
although
novel
gener
non
viral
deliveri
system
nanoparticl
protein
transduct
domain
peptid
modifi
liposom
character
low
toxic
immunogen
emerg
gener
interest
issu
diffus
promis
bring
new
improv
next
futur
